Cypriot Market Community

Cue Biopharma bets its future on a new allergy drug designed by the same scientist who created Xolair, aiming to make treatment far less frequent for people with chronic hives and other allergic conditions. A key mid-stage trial result is coming soon, and it could either put Cue on big pharma’s radar or expose just how risky this turnaround really is.

Adobe sits in the middle of the AI disruption debate, but the view here is that rivals will struggle to unseat it as the default toolset for creative and marketing work anytime soon. The key question is whether the market is overreacting to new AI tools and missing how sticky Adobe’s products and customer habits remain.

Broadcom isn’t just riding the buzz around artificial intelligence—it sells the behind-the-scenes tech that keeps data moving, connected, and secure across modern computing. If the world keeps demanding more computing and networking over the coming years, Broadcom could benefit even if today’s AI leaders change.

Okta now reaches profitability, but the bigger question is whether its CEO can turn that milestone into steady, lasting profit as customer loyalty slips. The story hinges on new pricing, added services, and even a possible tie-up with CrowdStrike to unlock the next phase.